Altimmune, Inc. 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K reports on the results of Altimmune, Inc.'s 2024 Annual Meeting of Stockholders held on September 26, 2024. As of the record date of August 12, 2024, there were 71,070,951 shares of common stock outstanding. A quorum was established with 43,676,304 shares (61.5%) present or represented by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1: Election of Directors. All eight nominees were elected. Notable vote splits included Wayne Pisano (15,375,257 For; 6,516,752 Withhold) and Philip L. Hodges (17,824,841 For; 4,067,168 Withhold). All other directors received over 21 million "For" votes.
- Proposal 2: Ratification of Auditors. The appointment of Ernst & Young LLP was ratified with 43,204,496 votes For, 315,411 Against, and 156,397 Abstain.
- Proposal 3: Say-on-Pay. The advisory vote on executive compensation was approved with 13,663,909 votes For, 7,992,177 Against, and 235,923 Abstain. There were 21,784,295 broker non-votes.
- Proposal 4: Adjournment Authorization. The proposal to authorize adjournment to solicit additional proxies was approved with 26,771,350 votes For, 16,249,120 Against, and 655,834 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific reasons for the significant "Withhold" votes for directors Wayne Pisano and Philip L. Hodges.
- Confirm the final outcome of the "Say-on-Pay" vote given the substantial number of "Against" votes (approx. 57% of votes cast excluding abstentions).
- Review the full Proxy Statement for details on executive compensation and director qualifications referenced in the voting results.
- Note that the filing was signed by Andrew Shutterly, Acting Chief Financial Officer.